Imatinib Mesylate Pellets

(Product under development)
Imatinib Mesylate PelletsImatinib (originally STI571) is a drug used to treat certain types of cancer. It is currently marketed by Novartis as Gleevec (USA) or Glivec (Europe/Australia/Latin America) as its mesylate salt, imatinib mesilate.

It is used in treating chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs) and some other diseases.

By 2011, Gleevec has been FDA approved to treat ten different cancers. In CML, the tyrosine kinase enzyme ABL is locked in its activated form.

It induces the abnormal phenotypes of CML, such as: excessive proliferation and high white blood cell count. Imatinib binds to the site of tyrosine kinase activity, and prevents its activity.

Imatinib is the first member of a new class of agents that act by specifically inhibiting a certain enzyme that is characteristic of a particular cancer cell, rather than non-specifically inhibiting and killing all rapidly dividing cells, and served as a model for other targeted therapy modalities through tyrosine kinase inhibition.

Availble Form:
Imatinib Mesylate Pellets
Imatinib Mesylate Granules

Umang Pharmatech equipments used for production of Imatinib Mesylate Pellets:
Drug Layering, Fluid Bed Dryer, Fluid Bed Coater, Sifter & Blender, Extruder and Twin spheronizer.

Imatinib Mesylate Pellets
Systematic (IUPAC) Name
Imatinib Mesylate Pellets
Imatinib Mesylate Pellets
Chemical data
CAS number : 152459-95-5 220127-57-1 (mesilate)
ATC code : L01XE01
PubChem : CID 3702
DrugBank : APRD01031
ChemSpider : 3574
UNII : F089I0511L
KEGG : D00345
Formula : C16H16ClN3O3S
Mol. mass : 365.835 g/mol

* All transactions are carried out in conformity with patent laws applicable in the user country. Active pharmaceutical ingredients or formulations thereof will not be supplied in countries where the same is under patent protection except as and if permitted under law of the country for research and development purposes only.
Extruder Spheronizer Email Us Umang Pharmatech